vimarsana.com
Home
Live Updates
ASCO24: Akesos bispecific vvonescimab faces a rocky road ahead in NSCLC : vimarsana.com
ASCO24: Akeso's bispecific vvonescimab faces a rocky road ahead in NSCLC
While commercial uptake may be difficult for ivonescimab, a positive regulatory decision would help validate Akeso's bispecific platform.
Related Keywords
United States ,
China ,
American ,
Chinese ,
Astrazeneca Tagrisso ,
Williamn William Jr ,
Akeso Tetrabody ,
Astrazeneca ,
Johnson ,
American Society Of Clinical Oncology ,
American Society ,
Clinical Oncology ,
Summit Therapeutics ,
North America Exclusive ,
Pharmaceutical Technology ,
vimarsana.com © 2020. All Rights Reserved.